Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs). In this section, a chart breaks down these medications according to their drug class. Also included is a timeline showing when each drug became FDA-approved as well as a guide to the generic, brand, and other alternate names for various drugs.

Classes: Mides, Mibs, MAbs and Others to Treat Multiple Myeloma

Drug Class Name Abbreviations Brand
Proteasome inhibitors ixazomib I Ninlaro®
carfilzomib cfz, car, K Kyprolis®
bortezomib btz, bor, V Velcade®
Immunomodulators       pomalidomide pom, P Pomalyst®
lenalidomide len, R Revlimid®
thalidomide thal, T Thalomid®
Alkylating agents melphalan mel, M Alkeran®, Alphalan®
cyclophosphamide       CTX, Cy, C Cytoxan®
Corticosteroids dexamethasone D, d, dex, DXM    Decadron®
prednisone pred, P Delatsone®
Histone Deactylase Inhibitors     panobinostat none yet Farydak®
Bisphosphonates zoledronic acid zol Zometa®
pamidronate pmd Aredia®
Monoclonal antibodies daratumumab dara Darzalex®
elotuzumab elo, E Empliciti®

Myeloma Drug Timeline

Guide to Drug Names

GENERIC NAME BRAND NAME ORIGINAL NAME

afuresertib

 

GSK2110183

bendamustine

Treanda®

SDX-105

bortezomib

Velcade®

PS-341

carfilzomib

Kyprolis®

PR-171

cyclophosphamide

Cytoxan®

 

dabrafenib

Tafinlar®

 

daratumumab

Darzalex®

CD38 mAb

dasatinib

Sprycel®

BMS-354825

denosumab

XGEVA®

AMG-162, osteoprotegerin

dinaciclib

 

SCH 727965

durvalumab

 

MED14736

eltrombopag

Promacta®

 

elotuzumab

Empliciti®

HuLuc63

everolimus

Afinitor®

LY317615

filanesib

 

ARRY-520

Ibrutinib

Imbruvica®

PCI-32765

indatuximab ravtansine

 

BT062

ipilumumab

Yervoy®

 

ixazomib

Ninlaro®

MLN9708

lenalidomide

Revlimid®

CC-5013

lirilumab

 

IPH-2102, BMS-986015

marizomib

 

NPI-0052, salinosporamide

masitinib

 

AB1010

melphalan

Alkeran®

 

nelfinavir

Viracept®

 

nivolumab

Opdivo®

BMS-936558

oprozomib

 

ONX-0912

palbociclib

Ibrance®

PD 0332991

pamidronate

Aredia®

 

panobinostat

Farydak®

LBH589

pegylated liposomal doxorubicin

Doxil®

 

pembrolizumab

Keytruda®

MK-3475-013

pidilizumab

 

CT-011

plerixafor

Mozobil®

AMD3100

plitidepsin

Aplidin®

 

pomalidomide

Pomalyst®

CC-4047

quisinostat

 

JNJ26481585

ricolinostat

 

ACY-1215

romidepsin

Istodax®

FK228, depsipeptide

selinexor

 

KPT-330

sirolimus

Rapamune®

rapamycin, AY 22989

sonidegib

Odomzo®

LDE225, erismodegib

sotatercept

 

ACE-011

temsirolimus

Torisel®

CCI-779

thalidomide

Thalomid®

 

trametinib

Mekinist®

GSK11202

ulocuplumab

 

BMS-936564

urelumab

 

BMS-663513

venetoclax

Venclexta®

ABT-199

vorinostat

Zolinza®

SAHA

zoledronic acid, zoledronate

Zometa®

 

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.